SCHEMBL7057657

SCHEMBL7057657

C[C@H]1CCC[C@](c2cccc(NC(=O)c3ccccn3)c2)(N2CCN(c3ccccc3)CC2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.47
EGFR P00533 2/20 0.46
ERBB2 P04626 2/20 0.46
MET P08581 2/20 0.46
MERTK Q12866 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 2/20 0.46
HTT P42858 2/20 0.46
NPC1 O15118 1/20 0.46
PKM P14618 1/20 0.46
RAB9A P51151 1/20 0.46
KLF5 Q13887 1/20 0.46
BACE1 P56817 2/20 0.44
NPY1R P25929 1/20 0.44
HCRTR1 O43613 2/20 0.44
HCRTR2 O43614 1/20 0.44
ACKR3 P25106 2/20 0.42
KCNK3 O14649 1/20 0.42
KCNK9 Q9NPC2 1/20 0.42
ALDH1A1 P00352 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7057653 1.00 KDR (0.47) KDREGFRERBB2METMERTK
SCHEMBL7051385 0.90 NPY1R (0.55) KDREGFRERBB2METMERTK
SCHEMBL7051383 0.90 NPY1R (0.55) KDREGFRERBB2METMERTK
SCHEMBL7050021 0.88 KCNK3 (0.44) SMN1; SMN2MAPTHTTNPC1RAB9A
SCHEMBL7050023 0.88 KCNK3 (0.44) SMN1; SMN2MAPTHTTNPC1RAB9A
SCHEMBL7054646 0.87 SMN1; SMN2 (0.54) SMN1; SMN2MAPTHTTNPC1RAB9A
SCHEMBL8397556 0.87 SMN1; SMN2 (0.54) SMN1; SMN2MAPTHTTNPC1RAB9A
SCHEMBL7054644 0.87 SMN1; SMN2 (0.54) SMN1; SMN2MAPTHTTNPC1RAB9A
SCHEMBL7055634 0.85 NPY1R (0.39) KDRSMN1; SMN2MAPTHTTNPC1
SCHEMBL7055539 0.84 MAPT (0.53) SMN1; SMN2MAPTNPC1RAB9AACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6316617-B1 FOR TREATING PHYSIOLOGICAL DISORDERS ASSOCIATED WITH AN EXCESS OF NEUROPEPTIDE Y, SUCH AS FEEDING DISORDERS AND CERTAIN CARDIOVASCULAR DISEASES, MEDICAL DIAGNOSIS NEUROGEN CORPORATION 2001-11-13 US claimed
EP-0918761-B1 CERTAIN AMIDO- AND AMINO-SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTITE Y1 SPECIFIC LIGANDS NEUROGEN CORP (US) 2003-05-02 EP disclosed
US-6316617-B1 FOR TREATING PHYSIOLOGICAL DISORDERS ASSOCIATED WITH AN EXCESS OF NEUROPEPTIDE Y, SUCH AS FEEDING DISORDERS AND CERTAIN CARDIOVASCULAR DISEASES, MEDICAL DIAGNOSIS NEUROGEN CORPORATION 2001-11-13 US disclosed
US-6133265-A Certain amido- and amino- substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands NEUROGEN CORPORATION (US) 2000-10-17 US disclosed